CVS Health CLO Departs, New CLO Appointed

TL;DR

CVS Health's CLO is out, new one in. Cohen takes over Nov 18.

AI Summary

CVS Health Corporation announced on November 12, 2024, the departure of its Chief Legal Officer, Thomas R. Robinson, effective November 15, 2024. The company also announced the appointment of David M. Cohen as the new Chief Legal Officer, effective November 18, 2024. This filing also includes information regarding compensatory arrangements for certain officers.

Why It Matters

A change in a key executive role like Chief Legal Officer can signal shifts in the company's legal strategy or risk management approach.

Risk Assessment

Risk Level: medium — Executive departures and appointments, especially for a CLO, can introduce uncertainty regarding legal and regulatory matters.

Key Players & Entities

• CVS Health Corporation (company) — Registrant
• Thomas R. Robinson (person) — Chief Legal Officer (departing)
• November 15, 2024 (date) — Effective date of Robinson's departure
• David M. Cohen (person) — New Chief Legal Officer
• November 18, 2024 (date) — Effective date of Cohen's appointment

FAQ

From the Filing

0001193125-24-260405.txt : 20241118 0001193125-24-260405.hdr.sgml : 20241118 20241118064553 ACCESSION NUMBER: 0001193125-24-260405 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241112 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241118 DATE AS OF CHANGE: 20241118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 241469727 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d828431d8k.htm 8-K 8-K CVS HEALTH Corp false 0000064803 0000064803 2024-11-12 2024-11-12     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2024         CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter)       Delaware   001-01011   05-0494040 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) One CVS Drive Woonsocket , Rhode Island 02895 (Address of Principal Executive Offices, and Zip Code) (401) 765-1500 Registrant’s Telephone Number, Including Area Code N/A (Former name, former address and former fiscal year, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.01 per share   CVS   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. On November 17, 2024, CVS Health Corporation (the “Company”) entered into a confidentiality agreement (the “Confidentiality Agreement”) w